Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07660432Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SIM0689 in solid tumor, sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 4 weeks, Maximum tolerated dose and / or Recommended dose at 2 years and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
SIM0689
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07660432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660432.